US FDA Explores Testing New Modeling, Simulation Approaches For Drug Trials
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration and the pharmaceutical industry appear interested in creating systems for testing simulation and modeling approaches to clinical trial design as part of prescription drug user fee program renewal (PDUFA VI).